Key Information
Source
summary/abstract
Cardiac amyloidosis (ICD-10 E85.4) is an infiltrative cardiomyopathy from amyloid fibril deposition. Per ESC 2023 cardiomyopathy guidelines, distinguishing ATTR from AL subtypes is critical and uses echocardiographic granular sparkling, cardiac MRI late gadolinium enhancement, technetium pyrophosphate scintigraphy with Perugini grading, and serum free light chains. Treatment includes chemotherapy or autologous stem cell transplantation for AL, while tafamidis, vutrisiran, and patisiran target ATTR with proven mortality benefit.